Stock Analysis Report

Header cover image

Executive Summary

Clínica Baviera, S.A. operates a network of ophthalmological clinics. More Details


Trading at 53.4% below our estimate of its fair value

Risk Analysis

No risks detected for CBAV from our risk checks.

Snowflake Analysis

Excellent balance sheet and good value.

Share Price & News

How has Clínica Baviera's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: CBAV is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CBAV's weekly volatility (4%) has been stable over the past year.

Market Performance

7 Day Return




ES Healthcare


ES Market

1 Year Return




ES Healthcare


ES Market

Return vs Industry: CBAV underperformed the Spanish Healthcare industry which returned -6.5% over the past year.

Return vs Market: CBAV underperformed the Spanish Market which returned -8.8% over the past year.

Shareholder returns

7 Day7.3%-1.3%0.7%
30 Day18.4%3.6%19.3%
90 Day17.0%2.1%17.5%
1 Year-16.9%-16.9%-4.3%-5.9%-6.2%-8.8%
3 Year33.4%25.8%-13.5%-17.7%-6.5%-14.9%
5 Year129.4%98.1%-1.9%-8.6%6.4%-9.7%

Long-Term Price Volatility Vs. Market

How volatile is Clínica Baviera's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Clínica Baviera undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: CBAV (€10.3) is trading below our estimate of fair value (€22.12)

Significantly Below Fair Value: CBAV is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: CBAV is good value based on its PE Ratio (19.2x) compared to the XE Healthcare industry average (26x).

PE vs Market: CBAV is good value based on its PE Ratio (19.2x) compared to the Spanish market (22.1x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBAV's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CBAV is overvalued based on its PB Ratio (5x) compared to the XE Healthcare industry average (1.9x).

Next Steps

Future Growth

How is Clínica Baviera forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Clínica Baviera has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has Clínica Baviera performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CBAV has high quality earnings.

Growing Profit Margin: CBAV's current net profit margins (10.1%) are lower than last year (10.4%).

Past Earnings Growth Analysis

Earnings Trend: CBAV's earnings have grown by 14.3% per year over the past 5 years.

Accelerating Growth: CBAV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CBAV had negative earnings growth (-4.2%) over the past year, making it difficult to compare to the Healthcare industry average (-0.3%).

Return on Equity

High ROE: CBAV's Return on Equity (31.1%) is considered high.

Next Steps

Financial Health

How is Clínica Baviera's financial position?

Financial Position Analysis

Short Term Liabilities: CBAV's short term assets (€26.8M) exceed its short term liabilities (€18.6M).

Long Term Liabilities: CBAV's short term assets (€26.8M) do not cover its long term liabilities (€56.5M).

Debt to Equity History and Analysis

Debt Level: CBAV's debt to equity ratio (27.1%) is considered satisfactory.

Reducing Debt: CBAV's debt to equity ratio has reduced from 80.3% to 27.1% over the past 5 years.

Debt Coverage: CBAV's debt is well covered by operating cash flow (260.1%).

Interest Coverage: CBAV's interest payments on its debt are well covered by EBIT (31.2x coverage).

Balance Sheet

Next Steps


What is Clínica Baviera current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBAV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBAV's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: CBAV is not paying a notable dividend for the Spanish market.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBAV's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Eduardo Baviera Sabater (52 yo)

no data




Mr. Eduardo Baviera Sabater serves as the Chief Executive Officer of Clínica Baviera, S.A. and served as its Executive Chairman since February 12 2007 and also served as its Managing Director. Mr. Baviera ...

CEO Compensation Analysis

Compensation vs Market: Eduardo's total compensation ($USD0.00) is below average for companies of similar size in the Spanish market ($USD541.26K).

Compensation vs Earnings: Eduardo's compensation has been consistent with company performance over the past year.

Board Members

Eduardo Baviera Sabater
CEO & Executive Directorno data€200.00kno data
Diego Ramos Pascual
Secretary & Independent Director12.42yrs€33.20k0.00031%
€ 515.5
Emilio Martínez
Independent Director1.58yrsno datano data
Bang Chen
Chairman3.33yrsno datano data
Shi Jun Wu
Director3.33yrsno datano data
Li Li
Director3.33yrsno datano data
Yongmei Zhang
Director3.33yrsno datano data


Average Tenure


Average Age

Experienced Board: CBAV's board of directors are considered experienced (3.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Clínica Baviera, S.A.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Clínica Baviera, S.A.
  • Ticker: CBAV
  • Exchange: BME
  • Founded:
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €166.289m
  • Shares outstanding: 16.30m
  • Website:

Number of Employees


  • Clínica Baviera, S.A.
  • Paseo de la Castellana nº 20
  • Madrid
  • Madrid
  • 28046
  • Spain


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBAVBME (Bolsas y Mercados Espanoles)YesCommon SharesESEURApr 2007
D9ZDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2007
0GWJLSE (London Stock Exchange)YesCommon SharesGBEURApr 2007
CBAVEBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURApr 2007


Clínica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company’s clinics offers...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 19:45
End of Day Share Price2020/12/04 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.